Emgality

Generic name: Galcanezumab
Drug class: CGRP inhibitors

Usage of Emgality

Emgality is a prescription medicine used to prevent migraines and treat episodic cluster headaches in adults. Emgality can help reduce the number of migraine days per month and reduce the number of cluster headache attacks each week.

Emgality is Calcitonin-gene related peptide antagonist. Emgality works by blocking a protein called calcitonin-gene related peptide (CGRP) which is involved in migraines and episodic cluster headaches, blocking CGRP helps reduce migraines and cluster headaches.

Emgality is given as a monthly injection under the skin (suBCutaneous injection) using a single-dose prefilled pen or a single-dose prefilled syringe after the first loading dose.

Emgality received FDA approval on September 27, 2018, for the preventive treatment of migraine in adults, then on June 4, 2019, it received FDA approval for the treatment of episodic cluster headaches in adults.

Emgality side effects

Common side effects of Emgality may include:

pain;

redness;

itching;

irritation where the medicine was injected.

Serious side effects of Emgality

Get emergency medical help if you have signs of an allergic reaction to Emgality: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

An allergic reaction to the active ingredient galcanezumab can occur several days after an injection.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Emgality

You should not use Emgality if you are allergic to galcanezumab.

Emgality is not approved for use by anyone younger than 18 years old.

Tell your doctor if you are pregnant. It is not known whether galcanezumab will harm an unborn baby. However, having migraine headaches during pregnancy may cause preeclampsia (dangerously high blood pressure that can lead to medical problems in both mother and baby). The benefit of preventing migraines may outweigh any risks to the baby.

It may not be safe to breast-feed while using galcanezumab. Ask your doctor about any risk.

Relate drugs

How to use Emgality

Usual Adult Emgality Dose for Migraine Prophylaxis:

Initial dose: 240 mg subcutaneously once Maintenance dose: 120 mg subcutaneously monthly Comments: -The first dose is a loading dose consisting of 2 consecutive subcutaneous injections of 120 mg each. -If a dose is missed, administer as soon as possible. Thereafter, dose can be scheduled from the date of the last dose.

Usual Adult Emgality Dose for Cluster Headache:

Initial Dose: 300 mg (three consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period. Maintenance Dose: 300 mg subcutaneously once a month until the end of the cluster period.

Comments:

-Each dose is administered as 3 consecutive subcutaneous injections of 100 mg each. -This drug is to be injected once a month for the length of a cluster period which may extend from several weeks to months. -If a dose is missed, administer as soon as possible. Thereafter, dose can be scheduled monthly from the date of the last dose.

Emgality injection is available as

single-dose prefilled pen (120 mg/mL solution)

single-dose prefilled syringe (120 mg/mL solution)

single-dose prefilled syringe (100 mg/mL solution)

Warnings

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

What other drugs will affect Emgality

Other drugs may interact with galcanezumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.